Clinical Evaluation of Sulindac (CLINORIL <SUP>®</SUP>) in the Treatment of Acute Upper Respiratory Tract Infection

DOI Web Site PubMed

Bibliographic Information

Other Title
  • 急性上気道炎に対するSulindac (CLINORIL <SUP>®</SUP>) の薬効評価
  • 急性上気道炎に対するSulindac(CLINORIL)の薬効評価--多施設二重盲検法によるIbuprofenとの比較
  • キュウセイ ジョウキドウエン ニ タイスル Sulindac CLINORIL
  • Clinical Evaluation of Sulindac (CLINORIL ^|^reg;) in the Treatment of Acute Upper Respiratory Tract Infection
  • Double-Blind Comparison with Ibuprofen
  • 多施設二重盲検法によるIbuprofenとの比較

Search this article

Abstract

A multi-clinic double-blind study in comparison with ibuprofen was conducted to evaluate the effectiveness, safety and usefulness of sulindac, a new non-steroidal analgesic/anti-inflammatory agent, in acute upper respiratory tract infection. Patients were treated with sulindac 150mg twice a day or ibuprofen 300 mg three times a day for 4 days.<BR>The effectiveness and usefulness were statistically analyzed and compared in 141 sulindac-treated and 150 ibuprofen-treated patients; safety was similarly assessed in 144 and 152 patients, respectively.<BR>The sulindac group was superior to the ibuprofen group in improvement of headache, low back pain and tonsil redness on the 3rd day, and in low back pain on the 5th day.<BR>Not statistically significant difference was observed in the final global evaluations of the effectiveness, safety or usefulness. Therefore, sulindac is considered to be a highly useful drug equivalent or superior to ibuprofen in the treatment of acute respiratory tract infection.

Journal

  • Kansenshogaku Zasshi

    Kansenshogaku Zasshi 57 (3), 260-272, 1983

    The Japanese Association for Infectious Diseases

Keywords

Details 詳細情報について

Report a problem

Back to top